After some wrangling on the cost Merck could charge for the 100 mg dose, NICE has now cleared Simponi for psoriatic arthritis. While that is good news, it also makes the J&J arbitration outcome just a little more expenseive — up or down.
Here is a bit of The Wall Street Journal’s coverage on it — do go read it all:
. . . .The National Institute for Health and Clinical Excellence, or NICE, said in final draft guidance that Simponi® will now be an option for treating active and progressive psoriatic arthritis in adults if used in place of the other tumor necrosis factor, or TNF, inhibitor treatments for the illness — etanercept, infliximab and adalimumab.
NICE said its backing is dependent on a patient-access scheme agreed between the manufacturer and the U.K.’s Department of Health, whereby Merck provides both of the available doses of golimumab of 50 milligrams and 100 mg to the NHS at the cost of the 50 mg dose. . . .
Do stay tuned.